Allurion Technologies

Allurion Technologies Inc is a medical device company that focuses on creating a best-in-class weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.

What Happened

Earnings

Equities

News

Eurozone

Commodities

Markets

Trading Ideas

ALUR

OUST

SCHL

TELA

Gold Down Over 1%; Micron Technology Shares Fall After Q2 Earnings

Stock,Market,Investments,Crashing,Market Down

Intraday Update

VVPR

Dow Tumbles Over 400 Points; Nike Shares Dip After Q3 Results

Stock Movers

Movers

AUID

BHAT

BNTC

GCTK

INNV

MCVT

PNBK

PSTV

RVSB

TNMG

USAR

XHLD

Why Ouster Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

Allurion Technologies Inc

Allurion Technologies, Inc. Warrants, each whole warrant exercisable to purchase 1.420455 shares of common stock at an exercise price of $8.10 per share of common stock

Press Releases

Allurion to Raise Approximately $7.4 Million of Gross Proceeds in Offering Priced At-the-Market

Allurion Relaunches in France

Allurion Announces Plans To Combine GLP-1 Therapy With The Allurion Balloon to Treat Obesity

Allurion to Raise Approximately $6.1 Million of Gross Proceeds in Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline

Allurion Announces Closing of Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline

Allurion to Participate in Upcoming Investor Conferences

Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity

Allurion to Report Fourth Quarter 2024 Financial Results on March 26, 2025

Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence

Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

The Beachbody Company, Inc. Class A Common Stock

Beachbody Co

Carriage Servs

E-Home Household Service Holdings Limited - Ordinary shares

E-Home Household Service

European Wax Center, Inc. - Class A Common Stock

European Wax Center

Frontdoor

H&R Block

Mister Car Wash

Mixed Martial Arts Group Limited Ordinary Shares

Mixed Martial Arts Group

MEDIROM Healthcare Technologies Inc. - American Depositary Share

MEDIROM Healthcare Techs

OneSpaWorld Holdings Limited - Common Shares

OneSpaWorld Hldgs

Wag Group

Regis

Service Corporation International Common Stock

Service Corp Intl

SunCar Technology Group Inc. - Ordinary Shares

SunCar Tech Gr

WW International

XWELL

YSX Tech. Co., Ltd - Class A Ordinary Shares

YSX Tech

Chardan Capital

Roth MKM

TD Cowen

Jefferies

Comments

Allurion Technologies

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga